2nd Quarter - Termination

EISAI INC. for EISAI INC.

Firm
Client
Income
—
Expenses
$350,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Jun 30, 2019

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Regulatory and legislative health care issues impacting pricing and access * Regulatory and legislative health care issues, including the 340B program * Issues related to diagnosis and treatment of Alzheimer's Disease * FDA Guidance on Alzheimer's Drug Development

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Potential Pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. * H.R. 1530/S. 595 -- Treat and Reduce Obesity Act of 2019 * Revisions to Medicare reimbursement programs Changes to reimbursement structure of Medicare Part D Program Changes to coverage policy for certain drugs in Medicare Part D program Proposed Part B International Pricing Index Demonstration program Proposed HHS rule on Rebates

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 595 (116th), H.R. 1530 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.